Pacerone Tablet
NDC Package 71610-787-30
Package Information
Pacerone (amiodarone hydrochloride) tablets is a medication used to treat certain types of serious (possibly fatal) irregular heartbeat (such as persistent ventricular fibrillation/tachycardia). This formulation utilizes a tablet delivery system. Marketed by Aphena Pharma Solutions - Tennessee, Llc, this product is identified by NDC 71610-787 and is authorized under FDA application ANDA075135.
Identification & Billing
- RxCUI: 833528 - amiodarone HCl 200 MG Oral Tablet
- RxCUI: 833528 - amiodarone hydrochloride 200 MG Oral Tablet
- RxCUI: 834346 - Pacerone 200 MG Oral Tablet
- RxCUI: 834346 - amiodarone hydrochloride 200 MG Oral Tablet [Pacerone]
Clinical Specifications
- Antiarrhythmic - [EPC] (Established Pharmacologic Class)
- Cytochrome P450 1A2 Inhibitors - [MoA] (Mechanism of Action)
- Cytochrome P450 2C9 Inhibitors - [MoA] (Mechanism of Action)
- Cytochrome P450 2D6 Inhibitors - [MoA] (Mechanism of Action)
- Cytochrome P450 3A Inhibitors - [MoA] (Mechanism of Action)
- P-Glycoprotein Inhibitors - [MoA] (Mechanism of Action)
Regulatory & Marketing
Hierarchy Structure
- 71610 - Aphena Pharma Solutions - Tennessee, Llc
- 71610-787 - Pacerone
- 71610-787-30 - 30 TABLET in 1 BOTTLE
- 71610-787 - Pacerone
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 71610-787-30 identifies a specific commercial package of 30 tablet in 1 bottle of Pacerone, a human prescription drug labeled by Aphena Pharma Solutions - Tennessee, Llc. This product is billed for "EA" each discreet unit and contains an estimated amount of 30 billable units per package. This tablet is formulated for oral use and contains amiodarone hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Aphena Pharma Solutions - Tennessee, Llc on November 15, 2010. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat certain types of serious (possibly fatal) irregular heartbeat (such as persistent ventricular fibrillation/tachycardia). It is used to restore normal heart rhythm and maintain a regular, steady heartbeat. Amiodarone is known as an anti-arrhythmic drug. It works by blocking certain electrical signals in the heart that can cause an irregular heartbeat.
How is this Aphena Pharma Solutions - Tennessee, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 71610078730. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.